Oxford BioMedica PLC (OXBDF)

[marcusl2]

Wet AMD
In a phase I clinical trial for wet AMD, a gene therapy called “Retinostat,” delivered by injection under the retina, has proven safe. It also continues to make proteins that inhibit abnormal blood vessel growth, called angiostatin and endostatin, for at least one year after injection. These proteins were measured in fluid samples taken from inside the eye. Future clinical trials will likely test whether Retinostat can block the growth of harmful blood vessels in patients with wet AMD and diabetic retinopathy.
hTTps://www.brightfocus.org/macular/article/gene-therapy-eye-disease